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DObjectives: Thoracic endovascular aneurysm repair (TEVAR) was introduced in 2005 to treat descending tho-
racic aortic aneurysms. Little is known about TEVAR’s nationwide effect on patient outcomes. We evaluated
nationwide data regarding the short-term outcomes of TEVAR and open aortic repair (OAR) procedures
performed in the United States during a 2-year period.
Methods: From the Nationwide Inpatient Sample data, we identified patients who had undergone surgery for an
isolated descending thoracic aortic aneurysm from 2006 to 2007. Patients with aneurysm rupture, aortic dissec-
tion, vasculitis, connective tissue disorders, or concomitant aneurysms in other aortic segments were excluded.
Of the remaining 11,669 patients, 9106 had undergone conventional OAR and 2563 had undergone TEVAR.
Hierarchic regression analysis was used to assess the effect of TEVAR versus OAR after adjusting for confound-
ing factors. The primary outcomes were mortality and the hospital length of stay (LOS). The secondary out-
comes were the discharge status, morbidity, and hospital charges.
Results: The patients who had undergone TEVAR were older (69.5  12.7 vs 60.2  14.2 years; P<.001) and
had higher Deyo comorbidity scores (4.6 1.8 vs 3.3 1.8; P<.001). The unadjusted LOS was shorter for the
TEVAR patients (7.7  11 vs 8.8  7.9 days), but the unadjusted mortality was similar (TEVAR 2.3% vs OAR
2.3%; P ¼ 1.0). The proportion of nonelective interventions was similar between the 2 groups (TEVAR 15.9%
vs OAR 15.8%; P¼ .9). The TEVAR and OAR techniques produced similar risk-adjusted mortality rates; how-
ever, the TEVAR patients had 60% fewer complications overall (odds ratio, 0.39; P<.001) and a shorter LOS
(by 1.3 days). The TEVAR patients’ hospital charges were greater by $6713 (95% confidence interval $1869 to
$11,556; P<.001). However, the TEVAR patients were 4 times more likely to have a routine discharge to home.
Conclusions: The nationwide data on TEVAR for descending thoracic aortic aneurysms have associated this
procedure with better in-hospital outcomes than OAR, even though TEVAR was selectively performed in pa-
tients who were almost 1 decade older than the OAR patients. Compared with OAR, TEVAR was associated
with a shorter hospital LOS and fewer complications but significantly greater hospital charges. (J Thorac Car-
diovasc Surg 2010;140:1001-10)The first successful open repair of a thoracic aortic aneu-
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The Journal of Thoracic and Cartions for the management of abdominal aortic aneurysm re-
pair in 1991 caused a major paradigm shift, and the latter
technique has become the primary surgical modality for
a significant number of patients with an isolated abdominal
aortic aneurysm.2-4 In 2005, consequent to the results of the
Phase II trial of the GORE TAG endovascular prosthesis
(WL Gore & Associates, Newark, Del), the technology
for thoracic endovascular aneurysm repair (TEVAR) was
approved in the United States for repair of descending
thoracic aortic aneurysms (DTAAs).5 Since then, the use
of stent grafts has increased and has expanded to include hy-
brid approaches for treating certain complex thoracic and
thoracoabdominal aneurysms, although many of these ap-
plications are off label.6
Several single-center reports have described the
intermediate-term outcomes of TEVAR.7,8 However, these
data have not provided insight into the nationwide utility
or effectiveness of the procedure. Typically, the success of
any surgical procedure will be dictated by its outcomes
and ease of use. Procedures that are easy to perform are
likely to be adopted by—and performed in—manydiovascular Surgery c Volume 140, Number 5 1001
Abbreviations and Acronyms
CI ¼ confidence interval
DTAA ¼ descending thoracic aortic aneurysm
FDA ¼ Food and Drug Administration
HCUP ¼Healthcare Cost and Utilization Project
ICD-9-
CM
¼ International Classification of
Diseases, Ninth Revision, Clinical
Modification
LOS ¼ length of stay
NIS ¼ US Nationwide Inpatient Sample
OAR ¼ open aortic repair
TEVAR ¼ thoracic endovascular aneurysm repair
Acquired Cardiovascular Disease Gopaldas et al
A
C
Dcenters. In contrast, technically challenging procedures are
likely to be restricted to a few high-volume centers.9 Thus
far, little is known about TEVAR’s nationwide use and ef-
fect on patient outcomes. Therefore, we compared the in-
hospital outcomes of TEVAR and open DTAA procedures
performed in the United States during the initial 2-year pe-
riod after Food and Drug Administration (FDA) approval.
MATERIALS AND METHODS
Data Source
Datawereobtained fromtheUSNationwide InpatientSample (NIS), ada-
tabase of hospital inpatient stays maintained by the Agency for Healthcare
Research and Quality as a part of theHealthcare Cost and Utilization Project
(HCUP).10We used only part of the post-FDA–approval data thatwere avail-
able; these data had been collected in 2006 and 2007. The NIS is the largest
all-payer inpatient care database, representing 90%of all hospital discharges
from nonfederal facilities in the United States and, thus, was particularly
suited for a nationwide comparison. The NIS has numerous internal quality
assurance procedures for checking the consistency and validity of data
(available from: www.hcup-us.ahrq.gov/db/quality.jsp). Furthermore, the
HCUP validates the NIS annually by comparing its contents with those of
2 similar databases, the National Hospital Discharge Survey and the
Medicare Provider Analysis and Review, to assess potential biases in the
data set (available from: www.hcup-us.ahrq.gov/db/nation/nis/nisrelated
reports.jsp). The NIS contains data on approximately 8 million hospital
stays annually from more than 1000 hospitals, although this number has
varied slightly on an annual basis. Weights based on sampling
probabilities for each stratum are used in the analysis to ensure that the
hospitals studied are representative of all US hospitals.
The variables available in the NIS database include patient and hospital
demographics, payer information, treating and concomitant diagnoses, in-
patient procedures, in-hospital mortality, and the hospital length of stay
(LOS) (the date of admission to the date of discharge). The NIS database
also captures up to 15 International Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9-CM) diagnostic and procedure codes
per admission.
The institutional review board of Baylor College of Medicine approved
the present study, which was deemed exempt from the informed consent re-
quirement because of the nonidentifiable nature of the data. The reported
data conformed to the data-use agreement for the NIS from the HCUP.
Additional information about the NIS is available from the Agency for
Healthcare Research and Quality (available from: www.hcup-us.ahrq.
gov/nisoverview.jsp).1002 The Journal of Thoracic and Cardiovascular SurPatient Selection
From the weighted NIS data for the calendar years 2006 and 2007, we
used the ICD-9-CM diagnosis and procedure codes (see Appendix 1)11 to
identify all patients aged 18 years or older who had had a diagnosis of
DTAA and had undergone open aortic repair (OAR) or TEVAR. Patients
with vasculitis, any connective tissue disorder, gonadal dysgenesis, aneu-
rysmal rupture, aortic dissection, or concomitant aneurysms in other aortic
segments were excluded, as were patients who had undergone both OAR
and TEVAR (because the database had no mechanism to indicate whether
these were intraoperative conversions or planned staged procedures). Be-
cause our study was retrospective, our analysis compared the outcomes
of the actual procedures, rather than the intent-to-treat.
The Deyo index was used to compare the 2 groups in terms of preoper-
ative morbidity.12 The Deyo index—a weighted comorbidity index modi-
fied from the Charlson comorbidity index—assesses 17 prespecified
comorbidities and is specifically designed to be used with administrative
databases, using more than 600 ICD-9-CM diagnosis codes to query spe-
cific comorbid diagnoses. In previous surgical studies, we and other inves-
tigators have demonstrated the feasibility of querying the NIS database for
cardiac surgical procedures.13,14 Up to 15 ICD-9-CM diagnosis codes were
recorded per patient. These codes were then used to produce a summary
Deyo index score for each patient. The Deyo index and its individual com-
ponents were used for risk adjustment in the statistical model.
Study End Points
The primary outcomes of interest for the present study were in-hospital
mortality, defined as death during the index hospitalization, and LOS. The
secondary end points were discharge status, in-hospital morbidity, and hos-
pital charges. Discharges were classified as either routine or nonroutine. A
routine discharge was defined as discharge home without any sort of home
health care, including home intravenous medication therapy. Nonroutine
discharges included discharge to a skilled nursing or intermediate care
facility or to home with home health care, as well as departure from the
hospital against medical advice.
All-cause in-hospital morbidity was recorded according to the ICD-9-
CM diagnosis codes. The following morbidity categories were assessed:
intraoperative/procedure-related complications, postoperative infections,
neurologic complications, renal complications, respiratory complications,
deep vein thrombosis, and pulmonary embolism. Intraoperative and
procedure-related complications were specifically defined as complica-
tions that occurred during a procedure or that were directly related to tech-
nical aspects of the procedure (see Appendix 2).
Statistical Analysis
Because of the large size of the NIS data sets, the Statistical Package for
Social Sciences, version 17.0 (SPSS, Inc, Chicago, Ill) complex module
was used for all statistical analyses. The Student t test and c2 statistics
were computed to examine intergroup differences in age, race, gender, pa-
tient income (by quartile, as encoded in the NIS databases), expected payer,
Deyo index score, mortality, hospital LOS, and discharge status. After uni-
variate analysis, multivariable analysis with hierarchic linear and logistic
regression methods was performed. Hierarchic logistic regression analysis
was used to examine the risk-adjusted association of the type of surgical
intervention with the in-hospital complications, mortality, and discharge
status. In-hospital complications were analyzed both as a whole and in sep-
arate categories. Hierarchic linear regression models were used to test risk-
adjusted associations between the type of operation and the number of
complications per admission, LOS, and hospital charges. Because of the
large sample size, we knew that our analyses could reveal differences
that were statistically significant but of minimal clinical significance.
Therefore, 3 different effect size statistics were computed to assess the
practical implications of our findings. Cohen’s d was calculated for contin-
uous data by using pooled standard deviations and was appropriately
weighted for unequal sample size.15 The phi (4) coefficient was computedgery c November 2010
TABLE 1. Patient demographics and baseline characteristics
Characteristic OAR (n ¼ 9106) TEVAR (n ¼ 2563) c2 or t P value Effect size*
Age (y) 60.2  14.2 69.5  12.7 31.888 < .001 0.67
Elective admission 7660 (84.1%) 2158 (84.2%) 0.009 .9 NA
Female 2918 (32.0%) 1041 (40.6%) 65.554 < .001 0.075
Primary expected payery 539.804 < .001 0.215
Medicare 3861 (42.4%) 1716 (67.0%)
Private insurance 4490 (49.4%) 641 (25.0%)
Income quartilez 216.621 < .001 0.138
First 1553 (17.6%) 683 (27.4%)
Second 1962 (22.2%) 685 (27.4%)
Third 2330 (26.4%) 592 (23.7%)
Fourth 2984 (33.8%) 537 (21.5%)
Hospital size (large) 7184 (78.9%) 1869 (72.9%) 132.385 < .001 0.107
Racex 163.174 < .001 0.141
White 5656 (88.7%) 1446 (78.2%)
Black 301 (4.7%) 190 (10.3%)
Deyo comorbidity score 3.3  1.8 4.6  1.8 31.75 < .001 0.72
For categorical variables, data are presented as number (%), and c2 test was used; for continuous variables, data are presented as mean  standard deviation, and t test was used.
OAR, Open aortic repair; TEVAR, thoracic endovascular aneurysm repair. *Cohen’s d was used for age and Deyo score, and phi (4) was used for female gender. Cramer’s V was
computed for all other variables. yValid data were available for 11,659 patients (99.9%). zValid data were available for 11,327 patients (97.1%). xValid data were available for
8224 patients (70.5%).
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computed for variables with more than 1 degree of freedom.16 The follow-
ing cutoff values were used to judge the computed effect sizes:< 0.33
(small), 0.33 to 0.55 (medium), and>0.55 (large). The correlation coeffi-
cient (R2 ) was used to assess the goodness of fit for the statistical model
and ranges from 0 to 1, with 1 being a perfect fit. For large sample sizes,
an R2 of 0.3 is considered acceptable.RESULTS
Patient Characteristics
For the 2-year period of interest, 11,669 patients with
a DTAA met our inclusion and exclusion criteria. Of these,
9106 (78%) had undergone conventional OAR and 2563
(22%) had undergone TEVAR.
The baseline characteristics were compared between the
patients who had undergone OAR versus TEVAR (Table
1). The patients who had undergone TEVAR were older
than those who had undergone OAR by almost 10 years
(P<.001) and had a significantly greater Deyo comorbid-
ity score (P<.001). In each group, the proportion of pro-
cedures was similar. The most common primary payer
was Medicare for TEVAR patients (66.9%) and private in-
surance for OAR patients (49.4%; P<.001). This discrep-
ancy resulted from the age difference between the 2
groups. The patients in the highest income quartile consti-
tuted the largest proportion of patients who had undergone
OAR (33.8%) and the smallest proportion who had under-
gone TEVAR (21.5%) compared with the other income
quartiles. The opposite trend was noted for patients in
the lowest income quartile. Most OARs (78.9%) and TE-
VARs (72.9%) were performed in hospitals with a large
bed size (per the HCUP definition10). The proportion of
white patients was greater in the OAR group than in theThe Journal of Thoracic and CarTEVAR group (88.7% vs 78.2%; P<.001); the opposite
was true for black patients (4.7% vs 10.3%; P< .001).
Although the prevalence of several comorbidities (Table
2) was significantly different between the 2 groups, the
effect sizes were<0.33 for all differences. The prevalence
of chronic peripheral vascular disease, previous cerebrovas-
cular disease, chronic pulmonary disease, peptic ulcer dis-
ease, diabetes mellitus, and chronic kidney disease was
greater in the TEVAR group than in the OAR group. How-
ever, a history of myocardial infarction and congestive heart
failure was more common in the OAR group than in the
TEVAR group.Mortality
The unadjusted outcomes are summarized in Table 3. The
risk-adjusted outcomes are summarized in Table 4. The in-
hospital mortality rate was 2.3% for both groups. After ad-
justment for confounding factors and comorbidities, the
type of surgical approach did not seem to affect the mortal-
ity risk. Increasing age correlated independently with
a greater risk of mortality after surgical intervention, but
gender and the comorbidity index did not (Table 4).Hospital LOS
The mean unadjusted LOS was 8.8  7.9 days for the
OAR patients and 7.6  11.1 days for the TEVAR patients
(P<.001). The median LOS was 7 days for the OAR pa-
tients (range 0-155 days) and 5 days for the TEVAR patients
(range, 1-151 days). Multivariable linear regression analy-
sis revealed that TEVAR was independently associated
with a shorter hospital LOS (by 1.3 days; P<.001). Female
gender was independently associated with a 1.5-daydiovascular Surgery c Volume 140, Number 5 1003
TABLE 2. Patient comorbidities
Comorbidity OAR (n ¼ 9106) TEVAR (n ¼ 2563) c2 P value 4
Chronic PVD 368 (4.0%) 564 (22.0%) 878.398 < .001 0.274
Previous MI 10 (0.1%) 10 (0.4%) 9.189 .005 0.028
Previous CHF 1441 (15.8%) 264 (10.3%) 48.896 < .001 0.065
Previous cerebrovascular disease 278 (3.1%) 205 (8.0%) 123.315 < .001 0.103
Chronic pulmonary disease 1306 (14.4%) 881 (34.4%) 527.618 < .001 0.213
Rheumatic disease 110 (1.2%) 42 (1.6%) 2.888 .09 0.016
Peptic ulcer disease 25 (0.3%) 24 (0.9%) 20.957 < .001 0.042
Mild liver disease 40 (0.4%) 5 (0.2%) 3.104 .1 0.016
Diabetes mellitus 854 (9.4%) 352 (13.7%) 40.943 < .001 0.059
Diabetic complications 63 (0.7%) 25 (1.0%) 2.149 .2 0.014
Hemiplegia or paraplegia 61 (0.7%) 26 (1.0%) 3.209 .09 0.017
Chronic kidney disease 388 (4.3%) 313 (12.2%) 224.128 < .001 0.139
HIV 10 (0.1%) 0 2.817 .1 0.016
Cancer 120 (1.3%) 36 (1.4%) 0.116 .7 0.003
Metastatic cancer 18 (0.2%) 5 (0.2%) 0.001 1.0 0.001
Data are presented as number (%). OAR, Open aortic repair; TEVAR, thoracic endovascular aneurysm repair; PVD, peripheral vascular disease;MI, myocardial infarction; CHF,
congestive heart failure; HIV, human immunodeficiency virus.
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Dincrease in the LOS (B ¼ 1.53; 95% confidence interval
[CI], 1.14-1.93; P<.001), and a unit increase in the Deyo
comorbidity index score was associated with a 1-day in-
crease in the hospital LOS (B ¼ 1.09; 95% CI, 0.65-1.52;
P<.001).Discharge Status
The discharge was routine for 65.2% of the TEVAR pa-
tients but only 45.3% of the OAR patients (P<.001), and
TEVAR was independently associated with a 4 times
greater likelihood of a routine discharge home (odds ratio,
4.76; 95% CI, 3.48-4.63; P<.001). In the multivariable
regression model, age did not affect the discharge status,
but female gender and greater comorbidity scores were
associated with lower odds of a routine discharge
(Table 4).TABLE 3. Unadjusted outcomes of TEVAR versus OAR
Outcome
OAR
(n ¼ 9106)
TEVAR
(n ¼ 2563)
P
value
Effect
size
Died during hospitalization 209 (2.3%) 59 (2.3%) 1.0 0*
Complications per patient 0.51  0.79 0.33  0.67 < .001 0.7y
Any complication 3428 (37.6%) 588 (22.9%)< .001 0.128*
Length of stay (d) 8.77  7.9 7.6  11.1 < .001 0.13y
Routine discharge 4126 (45.3%) 1671 (65.2%)< .001 0.188*
Intraoperative/procedure-
related complications
2066 (22.7%) 294 (11.5%)< .001 0.116*
Deep venous thrombosis 38 (0.4%) 50 (2.0%) < .001 0.073*
Infections 488 (5.4%) 140 (5.5%) .8 0.002*
Neurologic complications 217 (2.4%) 64 (2.5%) .7 0.003*
Pulmonary embolism 32 (0.4%) 6 (0.2%) .4 0.009*
Respiratory complications 951 (10.4%) 110 (4.3%) < .0010.089*
Renal complications 535 (5.9%) 157 (6.1%) .6 0.004*
Data are presented as number (%) or mean  standard deviation. OAR, Open aortic
repair; TEVAR, thoracic endovascular aneurysm repair. *Phi (4) was used to calculate
effect size. yCohen’s d was used to calculate effect size.
1004 The Journal of Thoracic and Cardiovascular SurOverall Postoperative Complications
Regarding postoperative complications, the total number
of complications per patient was analyzed using linear re-
gression analysis and adjusting for confounding variables.
The risk of any complication was analyzed using logistic
regression modeling. The linear regression analysis results
indicated that TEVAR was associated with 1 fewer compli-
cation for every 3 patients (B ¼0.334; P<.001), and TE-
VAR was associated with a lower risk of any complication
(odds ratio, 0.39; 95% CI, 0.26-0.58; P<.001). In a multi-
variable regression model, no baseline characteristic was
associated with the risk of postoperative complications ex-
cept for the Deyo comorbidity score, which approached sta-
tistical significance (odds ratio, 1.5; 95% CI, 0.99-2.57;
P ¼ .056).
Subgroup Analysis: Postoperative Complications
In-hospital complications were segregated into different
categories and analyzed further with logistic regression
models (Table 5) to predict the independent effect of
TEVAR versus OAR on each complication category. Re-
garding the specific categories of complications, TEVAR
was independently associated with fewer intraoperative/
procedure-related, neurologic, and respiratory complica-
tions; however, the incidence of pulmonary embolism, renal
complications, and infections did not differ between the 2
groups.
Hospital Charges and Cost
The unadjusted hospital charges were similar for the TE-
VAR and OAR patients ($116,329  $109,006 vs
$117,985  $80,823; P ¼ .5). However, after risk adjust-
ment using multivariable linear regression analysis, TE-
VAR was associated with an additional hospital charge of
$6713 (P< .01). Hospital charge information captured ingery c November 2010
TABLE 4. Independent predictors of outcomes
Death Routine discharge Any complication
Predictor P value Odds ratio 95% CI P value Odds ratio 95% CI P value Odds ratio 95% CI
Age (y) .01 1.079 1.017-1.145 .1 0.992 0.981-1.002 1.0 1.001 0.963-1.040
Female gender .2 1.243 0.886-1.743 < .001 0.798 0.715-0.889 .9 1.025 0.740-1.420
Deyo index .2 0.669 0.377-1.188 < .001 0.784 0.695-0.885 .056 1.500 0.990-2.274
TEVAR .9 1.033 0.682-1.564 < .001 4.014 3.481-4.628 < .001 0.385 0.256-0.578
CI, Confidence interval; TEVAR, thoracic endovascular aneurysm repair.
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but does not reflect how much the hospital services actually
cost or the specific amounts that the hospitals received in
payment. The cost/charge ratios, formulated by the NIS
for each hospital, were used to compute the estimated
cost incurred by the hospital per case. The unadjusted hos-
pital costs were lower for the TEVAR patients than for the
OAR patients ($46,636  $46,303 vs $48,974  $32,943;
P<.05). However, multivariable linear regression analysis
revealed that TEVAR was not independently associated
with any cost benefit (P ¼ .2).DISCUSSION
We analyzed the data from a large nationwide cohort of
patients who had undergone TEVAR for isolated DTAA.
Our results have provided detailed insight into the initial
US implementation of TEVAR as a surgical modality. On
average, the TEVAR patients were older than the OAR pa-
tients by almost 1 decade, and the TEVAR patients had
more comorbidities. These differences occurred because,
initially, TEVAR was primarily used for relatively high-
risk patients who could not tolerate OAR, the standard treat-
ment. Thus, OARs constituted 75% of the procedures for
isolated DTAA. If the pattern of increasingly widespread
use of endovascular repair for abdominal aortic aneurysms
can be extrapolated to DTAA repair, a strong potential ex-
ists for increasing the proportion of TEVAR cases.TABLE 5. Effect of TEVAR on outcomes after DTAA repair:
Hierarchic multivariable regression models
Variable
P
value
Odds ratio or
Exp (B) 95% CI R2
Intraoperative complications < .001 0.41 0.35-0.50 0.14
Infections .3 0.88 0.68-1.14 0.22
Neurologic complications < .001 0.16 0.09-0.29 0.60
Renal complications .3 0.87 0.67-1.14 0.26
Respiratory complications < .001 0.28 0.21-0.36 0.18
Pulmonary embolism .5 1.51 0.51-4.47 0.46
Any complication < .001 0.39 0.26-0.58 0.93
Total complications/patient < .001 0.33* 0.38 to0.29 0.11
Died during hospitalization .9 1.03 0.68-1.56 0.38
Length of stay (d) < .001 1.27* 1.76 to0.79 0.28
Routine home discharge < .001 4.01 3.48-4.63 0.25
*Multivariable linear regression used for continuous variable outcome measures.
TEVAR, Thoracic endovascular aneurysm repair; DTAA, descending thoracic aortic
aneurysm; R2, correlation coefficient; other abbreviations as in Table 4.
The Journal of Thoracic and CarThe most common primary payer for TEVAR patients
was Medicare, which correlated with these patients being
older. A greater proportion of TEVAR patients than OAR
patients were in the lowest quartile of income, and twice
as many black patients had undergone TEVAR as had un-
dergone OAR. One could speculate that these patients
were more likely to have more comorbidities, which would
have favored a less-invasive approach. In addition, because
of the relative lack of data supporting the long-term reliabil-
ity of TEVAR, OAR has been preferentially offered to
younger patients. A significantly greater proportion of fe-
male patients underwent TEVAR, but female gender was
not associated with greater mortality or morbidity risk in
the regression models. Female gender, overall, was associ-
ated with lower odds of a routine discharge after interven-
tion on the DTAA. A more detailed socioeconomic and
demographic analysis is needed to understand the dynamics
of this interaction. In addition, as clinicians gain experience
with time, the proportion of TEVAR procedures performed
in various socioeconomic, racial, and age groups is likely to
change.
For older patients, the LOS must be considered in the
context of the patient’s discharge status. Shorter LOSs
might not necessarily indicate better outcomes if the pa-
tients were discharged to nursing facilities or other health-
care venues. Because insurance companies have capped
payments, hospitals have tended to aggressively incorporate
social services early on in the care of these relatively com-
plex patients to mobilize them fairly quickly to nursing
facilities or arrange support services to shorten the hospital
LOS. Our analysis showed that both the LOS and the pro-
portion of nonroutine discharges were lower for TEVAR
patients, suggesting a less morbid surgical procedure asso-
ciated with quicker recovery.
Our analysis revealed that the mortality profiles for TE-
VAR and OAR were not different, even after risk adjust-
ment. The overall unadjusted mortality rate was 2.3% for
both groups. Although TEVAR was performed in patients
with more comorbidities, a critical review of the regression
model for mortality revealed that, surprisingly, the overall
comorbidity score was not associated with mortality. In
contrast, patient age had a significant independent effect
on mortality. We believe that, as TEVAR becomes more
widely adopted in the near future, the age difference be-
tween OAR and TEVAR patients is likely to disappear,diovascular Surgery c Volume 140, Number 5 1005
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though a propensity-matching analysis would be ideal for
answering this question, the sample weights and significant
age discrepancy between the 2 groups prevented us from
creating a large enough propensity-matched subsample of
patients to perform an adequately powered analysis. As
more data become available during the next few years, a pro-
pensity-matching analysis could become more feasible.
We found that TEVAR was independently associated
with fewer procedure-related, neurologic, and respiratory
complications than OAR, resulting in a 61% lower overall
complication rate and, therefore, a greater proportion of
routine discharges and shorter hospital LOSs. The lower in-
cidence of neurologic and respiratory complications associ-
ated with TEVAR was not surprising, considering that the
procedure involves no aortic cross-clamping, ischemic
time, or thoracotomy. However, the benefits realized by
the reduction in morbidity did not necessarily result in
less mortality for the TEVAR patients.
The incidence of renal complications in the 2 groups was
similar. The TEVAR patients were much older and received
larger amounts of contrast agent, both during the actual
procedure and during preoperative high-resolution computed
tomographic angiography. However, patients who undergo
OAR have transient renal ischemia because of aortic cross-
clamping,which is entirely avoidedwithTEVAR.Webelieve
these risk factors, althoughunique to each group, have similar
effects on the incidence of postoperative renal dysfunction.
However, certain relevant data, such as the quantity of intra-
venous contrast used, whether patients underwent preproce-
dural renal prophylaxis, and the preoperative creatinine
levels, were not available from the database we used.
We found that TEVARwas independently associatedwith
a shorter hospital LOS by 1.3 days and a median hospital
LOS of 5 days. As with any minimally invasive procedure,
a major selling point would be the shorter LOS, whichmight
result in lower hospital costs. However, the reduction in the
LOS was only modest; thus, its financial benefits were less
than what one might have anticipated. Although TEVAR
only moderately reduced the hospital LOS, after adjustment
for confounding factors, TEVAR was associated with a 4
times greater likelihood of a routine discharge to home
than was OAR. Thus, the main benefit of TEVAR seems
to be thatmost of the patients go home rather than to a skilled
nursing or long-term healthcare facility. However, our dis-
charge data did not include readmissions for complications
or hospital visits for follow-up computed tomography. This
was a limitation of our study because, compared with the
complications of OAR, complications resulting from endo-
vascular aortic stenting procedures are more likely to man-
ifest after the patient has been discharged home.
Our study found that TEVAR was associated with signif-
icantly greater hospital charges. Stent grafts are much more
expensive than the grafts traditionally used in OAR, and the1006 The Journal of Thoracic and Cardiovascular Suroverhead expenses of maintaining a hybrid suite to perform
TEVAR are greater than those of a typical operating suite.
This, and several other factors, have driven hospitals to
charge more for TEVAR procedures.
Because the TEVAR patients stayed in the hospital for
a shorter period, the overall cost to the hospital was approx-
imately $2300 less. However, the adjustment for confound-
ing factors, including the LOS, cancelled this benefit,
suggesting that the collateral/operating costs were similar
between OAR and TEVAR. However, stent grafts are ex-
pensive, and as more graft modules are used, hospitals are
more likely to lose revenue.17,18 Other expenses that
would further reduce the cost benefit include the costs of
additional graft modules to treat endoleaks and of follow-
up computed tomography, which is routine after TEVAR.
A more meaningful outcome variable would be hospital
profits, but our database did not contain the information
necessary to examine that variable.
A study by Orandi and colleagues19 was the first to exam-
ine the short-term (3-month) outcomes of TEVAR after the
stent grafts were approved by the FDA. The initial FDA ap-
proval in 2005 allowed thoracic endovascular stent grafts to
be marketed on a nationwide basis; however, by that time,
a few centers had already been using TEVAR to treat aneu-
rysms and other aortic disease for about 5 years. The famil-
iarity with TEVAR at these centers allowed them to use this
modality to treat thoracic aortic dissections, infections, rup-
ture, and traumatic injuries and to perform staged proce-
dures in patients with extensive aortic disease.
Modifications of conventional principles and the use of ad-
junct procedures such as carotid subclavian bypass and
transapical approaches20 have allowed surgeons to treat
evenmore extensive thoracic aortic diseasewith endovascu-
lar approaches. In addition, the availability of TEVAR as
a viable option has allowed surgeons to modify the open
surgical approach to facilitate the treatment of aortic aneu-
rysms in adjacent territories. For example, the use of the tri-
furcated graft technique to repair the aortic arch takes into
consideration the need to create an adequate ‘‘landing
zone’’ should the patient require TEVAR in the more distal
aorta in the future.
In 2002, Najibi and colleagues21 reported the first com-
parison of TEVAR with open surgical repair in a series of
18 patients. The control groups included a historic cohort
of patients who had undergone open repair during the pre-
vious 3 years. The short-term follow-up data showed that
the endovascular group had significantly shorter operative
times, shorter hospital and intensive care unit stays, and
less operative blood loss. In 2005, Bavaria and colleagues22
reported the findings of the Phase II multicenter trial that
compared the results of Gore TAG thoracic endograft place-
ment (n ¼ 140) with those of traditional open repair
(n ¼ 94). The cohort included a group of low-risk patients
selected according to stringent inclusion and exclusiongery c November 2010
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be associated with a lower incidence of spinal cord ische-
mia, fewer respiratory and renal complications, and a shorter
hospital LOS. The pivotal results of the Evaluation of the
Medtronic Vascular Talent Thoracic Stent Graft System
for the Treatment of Thoracic Aortic Aneurysms (VALOR)
trial supported the use of the Talent Thoracic Stent Graft
System as a safe and effective alternative to open surgical
repair in patients with DTAAs. These elderly patients, de-
spite their significant comorbidities, had low mortality at
30 days, and TEVAR showed superior performance with re-
spect to acute procedural outcomes and perioperative mor-
tality. Although each study had different limitations and
control group characteristics, the findings of our nationwide
evaluation are consistent with these published results.
Our study was subject to the limitations inherent to its ret-
rospective design and the nature of the database used. Our
data represent a snapshot of real-world surgical practice
in the first few years after FDA approval, during which
the effect of the learning curve on TEVAR could have
been substantial but would have been difficult to quantify.
The data set included all TEVAR and OAR patients in the
United States but only for a 2-year period. This sample, al-
though the largest to date, was not large enough to deter-
mine the specific effects of hospital characteristics (eg,
whether or not the hospital was a dedicated aortic center)
on the outcomes of TEVAR. However, making this determi-
nation will become more feasible as data from more recent
years become available.
The study’s retrospective design imposed selection
biases in terms of whether OAR or TEVAR was chosen
for a given patient. That said, database studies are typically
limited by the contents of the database, which might not in-
clude data regarding every potentially relevant variable. For
example, the NIS database does not include any information
regarding aneurysmal extent, size, or symptoms or the func-
tional status of the patient. Also, neurologic complications
had to be considered as a single outcome because no spe-
cific ICD-9-CM codes are available to differentiate between
postoperative paraplegia and stroke. In addition, only data
regarding the total LOS, reflecting the period from preoper-
ative admission to discharge, were available. Although the
postoperative LOS would be more useful for identifying
benefits specific to the procedure itself, this information
was not available.
Because of the administrative nature of the database, re-
porting bias could have been present owing to coding errors.
Statistically, such a bias should have affected the 2 groups
of patients equally. Also, hard end points such as mortality,
LOS, and hospitalization costs are less likely to be affected
by coding errors than are more subjective clinical end
points. Long-term follow-up data to capture future reinter-
ventions are not available from the NIS database. Similarly,
as reported in published studies, most failures of TEVARThe Journal of Thoracic and Caroccur after discharge, rather than during the index hospital-
ization.23 Therefore, because of the lack of follow-up or
readmission data in the NIS database, our conclusions re-
garding the in-hospital outcomes of TEVAR should not be
extrapolated to the short- or long-term outcomes. Despite
these limitations, the NIS database provided the best overall
sample for a nationwide assessment, because it included
data from a large, varied group of US hospitals.CONCLUSIONS
Our nationwide study has shown that TEVAR resulted in
outcomes that were comparable, if not superior, to those of
OAR for isolated DTAA, even though TEVAR was selec-
tively performed in patients whowere almost 1 decade older
than the OAR patients. Although a shorter hospital LOS and
greater odds of routine home discharge favored TEVAR, the
in-hospital mortality profiles of TEVAR and OAR were
similar. Likewise, TEVAR was not associated with any
risk-adjusted cost benefit compared with OAR, although
the effects of race, gender, and socioeconomic status on
the clinical value of TEVAR require additional study. The
primary benefit in the risk-adjusted morbidity profile for
TEVAR stemmed from the lower incidence of neurologic,
respiratory, and intraoperative complications. Follow-up
studies involving more extensive databases that capture
the readmission data, interventions, follow-up imaging
findings, and pertinent costs would be more informative
about the long-term effectiveness of TEVAR. Although
our findings should not be used to dictate changes in clinical
practice, the results have provided unique insights from
a nationwide perspective. This distinguishes them from
the findings of single-institution studies, which have proba-
bly been biased by local expertise and institutional culture.
The authors thank Stephen N. Palmer, PhD, ELS, for editorial
assistance.References
1. DeBakey ME, Cooley DA. Successful resection of aneurysm of thoracic aorta
and replacement by graft. JAMA. 1953;152:673-6.
2. Parodi JC, La Mura R. Endovascular aortic devices: The Parodi and Palmaz sys-
tem. Surg Technol Int. 1996;5:290-6.
3. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation
for abdominal aortic aneurysms. Ann Vasc Surg. 1991;5:491-9.
4. Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Translu-
minal placement of endovascular stent-grafts for the treatment of descending tho-
racic aortic aneurysms. N Engl J Med. 1994;331:1729-34.
5. Makaroun MS, Dillavou ED, Kee ST, Sicard G, Chaikof E, Bavaria J, et al. En-
dovascular treatment of thoracic aortic aneurysms: Results of the phase II multi-
center trial of the GORE TAG thoracic endoprosthesis. J Vasc Surg. 2005;41:1-9.
6. Adams JD, Angle JF, Matsumoto AH, Peeler BB, Arslan B, Cherry KJ, et al. En-
dovascular repair of the thoracic aorta in the post-FDA approval era. J Thorac
Cardiovasc Surg. 2009;137:117-23.
7. Fernandez V,Mestres G,Maeso J, Dominguez JM, AloyMC,MatasM. Endovas-
cular treatment of traumatic thoracic aortic injuries: Short- andmedium-term fol-
low-up. Ann Vasc Surg. 2010;24:160-6.
8. McPhee JT, Asham EH, Rohrer MJ, Singh MJ, Wong G, Vorhies RW, et al. The
midterm results of stent graft treatment of thoracic aortic injuries. J Surg Res.
2007;138:181-8.diovascular Surgery c Volume 140, Number 5 1007
Acquired Cardiovascular Disease Gopaldas et al
A
C
D9. Lee AM, Melby SJ, Damiano RJ Jr. The surgical treatment of atrial fibrillation.
Surg Clin North Am. 2009;89:1001-20, x-xi.
10. Healthcare Cost Utilization Project, Nationwide Inpatient Sample (NIS). Rock-
ville, MD: Agency for Healthcare Research and Quality; 2001.
11. International classification of diseases, 9th revision, clinical modification. 5th ed.
Washington, DC: US Department of Health and Human Services, Public Health
Service; 1988.
12. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for
use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:
613-9.
13. Gopaldas RR, Chu D, Dao TK, Huh J, LeMaire SA, Coselli JS, et al. Predictors of
surgical mortality and discharge status after coronary artery bypass grafting in
patients 80 years and older. Am J Surg. 2009;198:633-8.
14. LeMaire A, Cook C, Tackett S, Mendes DM, Shortell CK. The impact of race and
insurance type on the outcome of endovascular abdominal aortic aneurysm
(AAA) repair. J Vasc Surg. 2008;47:1172-80.
15. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale,
NJ: L. Erlbaum Associates; 1988.
16. LipseyMW.Design sensitivity: statistical power for experimental research. New-
bury Park, Calif: Sage Publications; 1990.
17. Birch SE, Stary DR, Scott AR. Cost of endovascular versus open surgical repair
of abdominal aortic aneurysms. Aust N Z J Surg. 2000;70:660-6.
18. Murphy EH, Beck AW, Clagett GP, DiMaio JM, Jessen ME, Arko FR. Combined
aortic debranching and thoracic endovascular aneurysm repair (TEVAR) effec-
tive but at a cost. Arch Surg. 2009;144:222-7.
19. Orandi BJ, Dimick JB, Deeb GM, Patel HJ, Upchurch GR Jr. A population-based
analysis of endovascular versus open thoracic aortic aneurysm repair. J Vasc
Surg. 2009;49:1112-6.
20. Szeto WY, Moser WG, Desai ND, Milewski RK, Cheung AT, Pochettino A, et al.
Transapical deployment of endovascular thoracic aortic stent graft for an ascend-
ing aortic pseudoaneurysm. Ann Thorac Surg. 2010;89:616-8.
21. Najibi S, Terramani TT, Weiss VJ, MacDonald MJ, Lin PH, Redd DC, et al.
Endoluminal versus open treatment of descending thoracic aortic aneurysms. J
Vasc Surg. 2002;36:732-7.
22. Bavaria JE, Appoo JJ, MakarounMS, Verter J, Yu ZF,Mitchell RS. Endovascular
stent grafting versus open surgical repair of descending thoracic aortic aneurysms
in low-risk patients: A multicenter comparative trial. J Thorac Cardiovasc Surg.
2007;133:369-77.
23. Neuhauser B, Greiner A, Jaschke W, Chemelli A, Fraedrich G. Serious compli-
cations following endovascular thoracic aortic stent-graft repair for type B
dissection. Eur J Cardiothorac Surg. 2008;33:58-63.Discussion
Dr John A. Kern (Charlottesville, Va). Thank you. I have noth-
ing to disclose.
Dr Gopaldas and his colleagues fromHouston have presented to
us the largest review to date of thoracic endovascular aneurysm
repair (TEVAR) versus open repair for isolated descending tho-
racic aortic aneurysms. This is a large database, and the results
were more or less as expected. These particular results square up
nicely with previously published reports, as you have pointed
out, and, in general, the lower surgical complications and lower
neurologic and respiratory complications should be looked on
favorably from a healthcare economics standpoint. Interestingly,
however, although the complications were lower in the TEVAR
patients, the procedure-related hospital stay and mortality was ac-
tually identical between the 2 groups. This is perhaps a little unex-
pected given the lower complications in the TEVAR group.
I would like to emphasize the study for what it is and what it is
not, and then I have 3 questions. First, the sheer number of patients
analyzed makes this study noteworthy, sample size is not an issue,
and TEVARwas proven safe and, indeed, perhaps superior to open
repair. In addition, this study represents a true broad snapshot, if
you will, of the real-world experience with the early widespread
adoption of what was at the time a new Food and Drug Adminis-1008 The Journal of Thoracic and Cardiovascular Surtration-approved technology, TEVAR, and it showed that it stood
up nicely to the reference standard, open repair. This is particularly
impressive when realizing that data was collected from more than
1000 hospitals nationwide, as you pointed out. Therefore, perhaps
the results are not too terribly skewed by the high-volume, experi-
enced academic referral centers where stent grafting technology
was developed, refined, and validated by the experts. Indeed, per-
haps some lower volume centers were included in this trial and
their data were analyzed, and this is good.
What is this study not? First, this study was not a prospective
randomized trial, and this study did not use propensity matching
to compare similar patients with subsequent outcomes. This study
did use an administrative database, which was probably very bare-
bones and, as you said, likely subject to coding errors and biases.
Although some patient demographics were collected—for exam-
ple, we saw that the TEVAR patients were older and perhaps
a bit sicker—we have no information concerning the actual nature,
pathology, location, extent, or size of the aneurysms treated. Thus,
it is possible that you were comparing apples and oranges. Second,
no information is known about the downstream subsequent conse-
quences after either TEVAR or open repair. This in fact is a partic-
ularly important feature of stent grafting, even more so now as we
tackle more complex and challenging aortic pathologic findings in
which type I endoleaks can be seen in as many as 20% of patients.
These situations obviously require significant downstream
resource use and expertise. The need for frequent reimaging and
reinterventions could make TEVAR a bit less attractive in the
long run for both patients and third-party payers. Although TE-
VAR might appear favorable compared with open repair during
the initial hospitalization, the cumulative cost and consequences
of subsequent hospitalizations and interventions are still unknown.
So I have 3 questions.
First, what do you hypothesize was the major mode of death in
the TEVAR group? Complications, specifically life-altering respi-
ratory and neurologic complications, appeared less frequently in
TEVAR, yet the mortality was similar. Is it possible the increased
mortality was related to the vascular access complications associ-
ated with the early adoption of TEVAR, and do you think these
vascular complications and mortality have improved in the 3
years?
DrGopaldas.Dr Kern, thank you for your very detailed perusal
of our manuscript and for your extremely valuable comments. My
first thing in response to your comment that we do not have infor-
mation on the follow-up, which is certainly a very valid point, one
thing that we do have to point out is that the routine discharge rates
were greater with TEVAR. Thus, an older patient was more likely
to go home, and, yes, come back for a reintervention, but then a pa-
tient of a similar age who had undergone open repair was probably
going to end up in a nursing home and stay there for a long time
and probably not go home. So, the critical issue here is we do
not have information on either of these, whether they go to a nurs-
ing home, how much it costs, or if they come back for reinterven-
tions for TEVAR procedures. That is certainly a limitation we
acknowledge.
In answer to your question about the mortality difference that
was not seen, which was actually interesting considering that
TEVAR independently predicted lower complications. To address
this, we analyzed our groups separately, TEVAR patients and opengery c November 2010
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actually were the predictors of mortality within these groups. Also,
I am going to point out 2 factors: one is intraoperative complica-
tions, the other is respiratory complications.
Now, TEVAR independently predicted a lower incidence of in-
traoperative complications; however, in the regression model sep-
arately, when an intraoperative complication occurred in the open
aortic repair group, it did not independently translate to mortality.
The odds ratio was 1.3, but the P value was not significant. In con-
trast, in a TEVAR patient, if they developed an intraoperative com-
plication, the P value was significant and the odds ratio was about
4.5. So what this tells us is TEVAR does decrease the incidence of
intraoperative complications, but when an intraoperative compli-
cation does occur in a TEVAR patient, it is more likely to result
in a grave consequence, such as death.
The same issue occurred with renal complications, because
TEVAR did not translate to any difference in renal complications,
but when we separately analyzed the 2 groups, a renal complica-
tion in an open aortic repair was associated with a 5 times risk
of mortality, but in a TEVAR patient, a renal complication was as-
sociated with a 12 times risk of mortality.
So what I think we are seeing here are 2 things: one is the effect
of TEVAR on the incidence of these complications and the second
is the failure to rescue. Also, I think when TEVAR patients develop
a complication, the failure to rescue from these complications by
either the surgical team or the hospital was higher, and, as a result,
they faced a greater mortality. I believe this is what seems to
compensate and balance out the advantages of TEVAR and thus
contributing to no overall difference.
To look at the other aspect, the length of stay was not different.
We do not have information on the postoperative length of stay. So
that is another limitation.
Dr Kern. That is a good analysis of those results.
Do you have any information from this database of the results
as they compare to high-volume or low-volume centers? These
data were captured when pretty straightforward aneurysms were
being treated. You can see how lower-volume centers can treat
that and do it well. We are starting to treat very complex aortic
pathologic features. So, based on whether you know the results
of low- versus high-volume centers, when it comes to very diffi-
cult dissections and disorders like that, should those still be treated
by everyone?The Journal of Thoracic and CarDrGopaldas. That is certainly a very valid question. One of the
factors we included in our analysis was hospital size, and that did
not seem to affect the outcome of these procedures, although I
must say this is an isolated descending thoracic aneurysm, which
is fairly straightforward. Also, these cases, if a community hospital
can do it well, it probably should be done there, rather than just
being referred to an aortic center. The primary care physician is
probably going to find a cardiologist or a vascular surgeon who
can just push a guide wire up higher into the arch and deploy these
stents, and these patients are not going to be knocking on the door
of cardiac surgeons. But then if you are looking at complex aortic
procedures, such as an arch in which extensive debranching is
required or a thoracoabdominal aneurysm, that is a separate issue.
For those patients, data are already available that have supported
that performing these complex procedures in high-volume centers
is justified. So for a straightforward isolated descending, I do not
think these patients need to be shunted to an aortic center per se,
but when it is complex requiring some debranching, absolutely,
I think.
DrHanni Shennib (Phoenix, Ariz). I enjoyed your presentation
very much, and it actually confirms a lot of the other meta-analyses
that were done more recently, including a publication in the
American Journal of Cardiology. The question I have to you is
a follow-up on your comment regarding intraoperative complica-
tions and that the risk and complication rate, including risk and
mortality, and what you quoted as rescue issues seems to be higher
in the TEVAR group than in the open group. Can you perhaps
retrieve information regarding who is billing for the procedure,
whether it is co-billed between a cardiologist or an interventional-
ist and a surgeon versus the whole operation being done by an
endovascular surgeon and perhaps come to some findings in regard
to the failure to rescue? How many of those procedures, the
TEVAR procedures, are done primarily by the endovascular
service (i.e., billed by the endovascular service) versus billed by
the cardiologist or interventional radiologist in the presence of
a surgeon?
Dr Gopaldas. That information, unfortunately, is not available
in this database. The Medicare database captures that in more de-
tail, but this database does have that limitation. It does not differ-
entiate between who is doing it. Whether a vascular surgeon or an
interventionalist or a cardiologist or a cardiac surgeon is doing the
procedure cannot be addressed with this database.diovascular Surgery c Volume 140, Number 5 1009
APPENDIX 1. International Classification of Diseases, Ninth Revision,
Clinical Modification codes used for inclusion/exclusion of study group
patients
Codes used for inclusion
441.2 Diagnosis code: Thoracic aneurysm without mention
of rupture
39.73 Procedure code: Endovascular implantation of graft
in thoracic aorta
38.45 Procedure code: Resection of vessel with replacement;
thoracic aorta
Diagnosis codes used for exclusion
441.1 Thoracic aneurysm, ruptured
441.3 Abdominal aneurysm, ruptured
441.4 Abdominal aneurysm without mention of rupture
441.5 Aortic aneurysm of unspecified site, ruptured
441.6 Thoracoabdominal aneurysm, ruptured
441.7 Thoracoabdominal aneurysm, without mention of
rupture
441.9 Aortic aneurysm of unspecified site without mention
of rupture
441.00 Aortic dissection, unspecified site
441.01 Aortic dissection, thoracic
441.02 Aortic dissection, abdominal
441.03 Aortic dissection, thoracoabdominal
446.0 Polyarteritis nodosa
446.1 Kawasaki disease
446.2 Hypersensitivity angiitis
446.3 Lethal midline granuloma
446.4 Wegener’s granulomatosis
446.5 Giant cell arteritis
446.6 Thrombotic microangiopathy
446.7 Takayasu disease; aortic arch arteritis
758.6 Turner syndrome; gonadal dysgenesis
759.82 Marfan syndrome
Procedure codes used for exclusion
39.73þ38.45 Indicates conversion during, or reintervention after,
thoracic aneurysm repair
39.71 Endovascular implantation of graft in abdominal aorta
38.44 Resection of vessel with replacement; abdominal aorta
APPENDIX 2. International Classification of Diseases, Ninth Revision,
Clinical Modification codes used to identify procedure-related
complications
423.0 Hemopericardium
997.1 Cardiac arrest or cardiorespiratory failure
996.0 Mechanical complication due to an implant/graft
996.74 Thrombosis, fibrosis, hemorrhage, embolism due to
vascular graft
998.31 Disruption of surgical wound
997.71 Vascular complications of mesenteric artery
998.0 Postoperative shock
998.11 Hemorrhage
998.12 Hematoma
998.13 Seroma
E878.2 Surgical procedure using prosthetic vascular graft directly
causing abnormal patient reaction/complication
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